Clinical trials: Shy-Drager Syndrome
Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders
Study Rationale: No accurate tests currently exist to diagnose Parkinson's disease (PD) and the conditions which mimic it (atypical parkinsonism) at a very early stage.
- Conditions
- Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05638477
- Testing
- Free-viewing eye tracking
- Where
- Ireland
- Volunteers
- 122 people
- Sponsor
- Conor Fearon
Multiple System Atrophy
Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy
The main objective of the study is to compare the score to the Behavioral Dysexecutive Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and cerebellar Multiple System Atrophy (MSA-C) patients…
- Trial name
- CogAMS (NCT02185677)
- Testing
- Clinical evaluation, neuropsychological battery test, MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Parkinson's Disease, Multiple System Atrophy
Clinical Laboratory Evaluation of Chronic Autonomic Failure
Background: The autonomic nervous system controls automatic body functions. Researchers want to improve the tests used to diagnose autonomic failure. Orthostatic hypertension is a drop in blood pressure when a person stands up.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT03648905
- Testing
- 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB)
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease, Parkinsonism
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism.
- Conditions
- Parkinson's Disease, Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- VISMEMO-PD (NCT07827963)
- Testing
- Multimodal visuospatial and topographical memory assessment
- Where
- 3 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Parkinson Disease, Multiple System Atrophy, Parkinson Variant
Automated Imaging Differentiation of Parkinsonism
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
- Trial name
- AIDP (NCT05913687)
- Testing
- AIDP
- Where
- 21 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of Florida
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics
Hypertension, Pure Autonomic Failure
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension).
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT03042988
- Testing
- Heating pad
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Multiple System Atrophy, Parkinson Variant (Disorder)
DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism
Multiple system atrophy (MSA) is a debilitating and fatal neurodegenerative disorder and symptomatic therapeutic strategies are still limited.The parkinsonian type of MSA (MSA-P) has parkinsonian symptoms as its prominent…
- Trial name
- NCT04617873
- Testing
- Bilateral STN-DBS and T10-T12 SCS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- zhangyuqing
Multiple System Atrophy
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
The present study aims to conduct a randomized controlled trial to evaluate the efficacy and safety of 3-n-Butylphthalide (NBP) in improving symptoms in patients with Multiple System Atrophy (MSA).
- Trial name
- ENMSA (NCT07518810)
- Testing
- 3-N-butylphthalide
- Where
- 7 sites in China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Multiple System Atrophy, Parkinson Variant
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P).
- Trial name
- NCT07825402
- Testing
- ONO-2808
- Volunteers
- 486 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Multiple System Atrophy
Respiratoy Muscle Strength in Patients With Multiple System Atrophy
The purpose of this study is; compare respiratory function parameters and respiratory muscle strength in patients with MSA compare to healthy controls, and to evaluate the results of SNIP and PImax in measuring inspiratory muscle…
- Trial name
- NCT04287270
- Testing
- Assesment
- Where
- Turkey (Türkiye)
- Volunteers
- 19 people
- Sponsor
- Marmara University
Multiple System Atrophy
Medical Decision Making in Multiple System Atrophy
The goal of this clinical study is to evaluate the effects of a personalized symptomatic treatment plan integrated with monthly telemedicine and mobile palliative care interventions on a population of individuals diagnosed with…
- Trial name
- MeDeMSA (NCT06072105)
- Testing
- Telemedicine visits, Multidisciplinary, personalized symptomatic treatment
- Where
- Austria
- Volunteers
- 92 people
- Sponsor
- Medical University Innsbruck
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis)
Invasive Home Ventilation in Denmark
The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark.
- Conditions
- Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis), Spinal Cord Injuries (SCI), Duchenne Muscular Dystrophy (DMD)
- Trial name
- HOMEVENT DK (NCT07467187)
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple System Atrophy
Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
MSA is a rapidly progressive disorder with an average survival time of about 7 years after the first clinical manifestation. No potent symptomatic treatment is currently available.
- Trial name
- PROMESA (NCT02008721)
- Testing
- EGCG as putative neuroprotective agent
- Where
- 12 sites in Germany
- Volunteers
- 92 people
- Sponsor
- Dr. Johannes Levin
Shy-Drager Syndrome, Multiple System Atrophy
Water and Sudafed in Autonomic Failure
The specific aim of this study is to determine whether water ingestion potentiates the pressor response to pseudoephedrine in patients with primary disorders of autonomic failure.
- Trial name
- NCT02149901
- Testing
- Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vanderbilt University
Progressive Supranuclear Palsy, Cortico Basal Degeneration
Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes
The study will compare health care utilisation and quality of life for patients with progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy in different parts of the region that our specialist clinic…
- Conditions
- Progressive Supranuclear Palsy, Cortico Basal Degeneration, Multiple System Atrophy
- Trial name
- UHSQOLAPS (NCT06645626)
- Where
- United Kingdom
- Volunteers
- 198 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma